Digital Biomarkers
Digital tools, such as smartphone and wearable
devices, can now measure and collect health
information – or Digital Biomarkers – and help
improve research for new treatments in neuroscience
Digital Biomarkers
Digital tools, such as smartphone and wearable devices, can now measure and collect health information – or Digital Biomarkers – and help improve research for new treatments in neuroscience
Swiss MedTech Award 2022 Finalist
Healios AG is honored to have been picked as a finalist at the prestigious Swiss MedTech Award 2022
Digital Biomarkers change how chronic conditions are understood and treated
People living with chronic conditions need ongoing precise monitoring in order to optimally understand their condition evolution
Digital Biomarkers can measure patient symptoms precisely and objectively, over long periods of time
Digital Biomarkers have many benefits over conventional assessments
- Provide continuous and highly precise measurements
- Measure drug effect in “high definition”
- Are captured in daily life setting
Use of Digital Biomarkers in R&D has the potential to shorten the duration of clinical trials
- Gain early insights into drug effect within weeks
- Improved clinical trial efficiencies
- Reduced overall costs
Growing demand for decentralized clinical trials (due to the Covid pandemic amongst other reasons), Digital Biomarkers will become key components of future scientific research being:
- Highly reliable and precise
- Timely – data available within days
- Tailored to the study and the patient
- Independent from HCP bias
- Performed without help from clinicians
Patient Digital Phenotyping
Opening new avenues to research and treatment personalisation
Digital Biomarkers offer a more comprehensive picture of how a person living with a condition may be experiencing a variety of symptoms and how such symptoms affect their quality of life.
Digital Biomarkers open the door to a new level of patient phenotyping
For researchers engaged in neuroscience drug development, Digital Biomarkers offer several unprecedented benefits
Digital Biomarkers have the potential to change how future treatments will be developed and open the door to genuine treatment personalisation. Both patients and physicians will benefit greatly from such innovation.
- Digital Biomarkers minimize bias associated with pattern recognition
- Modern consumer devices (smartphone and wearables) can collect reliably and continuously accurate and objective data
- Digital Biomarkers are a cost-effective way to collect large amounts of data in a consistent manner
- Recent FDA and EMA guidelines endorse Digital Biomarkers as innovative endpoints
Where can Healios
Digital Biomarkers
be applied?
There is a significant unmet need in subjective medical domains (neurology and psychiatry) for precise and unbiased assessment.
Healios Digital Biomarkers are currently applied in multiple sclerosis and have potential application in many diseases in neuroscience as well as rare diseases.
The Healios AG team is keen to explore new disease areas with research teams globally where Healios Digital Biomarkers can make a positive difference for patients and improve their lives
Establishing a new standard in
precision Neuroscience
Healios AG is a Medical Device Software Manufacturer that is dedicated to finding solutions in clinical research and patient monitoring through innovative digital technologies.
With novel, validated and patented Digital Biomarkers, we aim at measuring – with unprecedented sensitivity – changes in motor and cognitive functions in patients with neurological disorders